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Abstract: 
Background: Data are sparse on long-term toxicity of antiretroviral therapy (ART) in HIV-infected 
children.  PENPACT-1 was an open-label trial randomizing HIV-infected children to protease inhibitor 
(PI)- vs non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART.  
Methods: We examined changes in clinical, immunologic and inflammatory markers from baseline to 
year 4 in the subset of PENPACT-1 children who had viral suppression between week 24 and year 4 of 
ART. Liver enzymes, creatinine, cholesterol and hematologic parameters were assessed during the trial. 
Cystatin C, hs-CRP, IL-6, d-dimer and sCD14 were assayed from cryopreserved specimens. 
 Results:  Ninety-nine children (52 on PI- and 47 on NNRTI-based ART) met inclusion criteria. Median age 
at initiation of ART was 6.5 years (IQR 3.7 – 13.4), with 22% age < 3 years at ART initiation; 56% of PI-
treated children received lopinavir/ritonavir and 70% of NNRTI-treated children received efavirenz 
initially.  There was no evidence of significant clinical toxicities in either group, with growth, liver, kidney 
or hematologic parameters either unchanged or improved between baseline and year 4. Total 
cholesterol levels increased modestly, with no difference between groups.  IL-6 and hs-CRP showed 
greater decrease after 4 years in the NNRTI based ART group. The change in IL-6 was -0.35 pg/ml in the 
PI group vs -1.0 in the NNRTI group (p=0.05) and the change in hs-CRP was 0.25 µg/ml PI vs -0.95 NNRTI 
(p=0.005). 
Conclusion: These results support the safety of prolonged ART use in HIV-infected children and suggest 
that suppressive NNRTI-based regimens may be associated with lower levels of systemic inflammation.   
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Introduction  
Combination antiretroviral therapy (ART) has significantly improved the outcome of HIV disease in 
children. While protease inhibitor (PI)-based therapy has been shown to have improved virologic 
outcome in children less than 3 years of age1, no antiretroviral (ARV) class has shown consistent 
superiority in regards to virologic suppression in older children. Thus clinicians select ARV regimens 
largely on availability and short term toxicity as data are sparse on the long-term toxicity profiles of 
differing ART regimens in HIV-infected children. In spite of improved immune function and long term 
viral suppression, chronic HIV infection in adults is associated with increased morbidity and mortality 
from non-AIDS related conditions including cardiovascular, renal, hepatic and neurologic disease2,3. 
While the reasons for this are multifactorial, long-term morbidity of treated HIV infection is thought to 
be due in part to chronic inflammation which is not completely ameliorated by ART3-5.  Although non-
AIDS related clinical morbidity in children is less well demonstrated because of their overall lower risk 
for these conditions, the cumulative effect of a prolonged inflammatory state is likely to be significant 
given the duration of HIV infection and need for life-long ART starting from infancy.  Studies in HIV-
infected adolescents have demonstrated increased risk for future cardiovascular, bone and renal 
disease6-9. Therefore even small differences in ART toxicity and inflammatory markers may be clinically 
significant over time in ART treated children.  
PENPACT-1 was a long-term international open label 2x2 factorial design trial randomizing HIV-infected 
children to PI-based vs non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART and to switch 
to second line therapy at high vs low viral load10. In the primary analysis, there was no difference 
between treatment or switch criteria in virologic outcome and serious adverse events. The long-term 
nature of this trial provides the opportunity to further explore ART toxicity and markers of inflammation 
in ART treated children.  
5 
 
Methods  
Population: At the start of the study, children participating in PENPACT-1 were either ART-naïve or had 
received ARVs for less than 56 days as part of prevention of mother-to-child transmission.  Children 
were randomized to start two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a PI or 
NNRTI and to switch from first-line to second-line ART at a viral load threshold of 1000 copies/ml or 
30,000 copies/ml: none of the children in the current analysis switched to second line therapy during 
the trial.  The specific ARTs were chosen by the treating clinician according to the randomized group.  
Drug substitutions within the same class were allowed for non-virologic reasons such as toxicity or 
change in availability. Children participating in PENPACT-1 who had no confirmed viral load >400 
copies/ml between week 24 and year 4 after ART initiation and had samples available for testing from 
baseline and after year 3  were included in this analysis.  Post-year 3 samples were selected as close to 
year 4 as possible.  
 
Clinical assessments: Children had assessments including growth, liver enzymes, creatinine, complete 
blood count and quantitative HIV RNA at screening, baseline, weeks 2, 4, 8, 12, 16, 24 and then every 12 
weeks until the last randomized child reached 4 years of follow-up.  Non-fasting triglycerides and 
cholesterol were measured at baseline and every 24 weeks throughout the trial. Laboratory assessments 
were performed at the local study site according to standard procedures.   
 
Cystatin C, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), d-dimer and soluble (sCD14) 
were measured from stored cryopreserved specimens from either screening or baseline and the closest 
available sample to year 4 by the Laboratory for Clinical Biochemistry Research at the University of 
Vermont.  HsCRP and cystatin C were measured using the BNII nephelometer (Siemens Healthcare 
Diagnostics, Deerfield, IL). IL-6 was measured by ultrasensitive chemiluminescent enzyme-linked 
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immunosorbent assay (ELISA) (Quantiglo HSHuman IL-6 Immunoassay; R&D Systems). Soluble CD14 was 
measured with an enzyme-linked immunosorbent assay (QuantikinesCD14 Immunoassay, R&D Systems).  
D-dimer levels with immunoturbidometric methods on the Sta-R analyzer, Liatest D-DI (Diagnostica 
Stago, Parsippany, NJ).   
 
Statistical analysis: Participant baseline characteristics were compared between treatment arms using 
Fisher’s exact test, chi-square tests, or Wilcoxon rank-sum tests as appropriate. Medians and 
interquartile ranges (IQR) were calculated for clinical measures at baseline and year 4. Changes in 
clinical measures were calculated as the value at 4 years minus baseline. The medians, their distribution-
free 95% confidence intervals11 and interquartile ranges were calculated for the changes in clinical 
measures from baseline to year 4. Changes in clinical measures were compared between the two 
treatment arms using Wilcoxon rank-sum tests. The analyses presented were exploratory; two-sided p-
values ≤0.05 were identified as statistically significant with no adjustment for multiple tests. Statistical 
analyses were conducted using SAS v. 9.4 (SAS Institute, Cary, NC). All analyses were as-treated.  Height, 
weight and BMI z-scores were calculated based on British 1990 growth centiles12. 
Results   
Population:  Ninety-nine children (52 on PI- and 47 on NNRTI-based cART) from countries in Europe and 
the Americas maintained viral suppression on their initial ART regimen and had stored samples available 
from either screening or baseline and close to year 4 (Error! Reference source not found.Table 1). 
Samples from screening or baseline were initially drawn between 9/2002 and 1/2005 and the year 4 
samples between 6/2005 and 4/2009 (median year 4 study week was 192; range weeks 141-216). Two 
participants originally randomized to the NNRTI arm substituted a PI within the first 2 weeks of 
treatment due to adverse events and were included in the PI group for these analyses. Median age at 
initiation of ART was 6.5 years (IQR 3.7 – 13.4), with 22% age < 3 years at ART initiation, and 53% were 
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male. The median baseline viral load was 5.1 log copies/mL (IQR 4.6 – 5.6) and median CD4% was 15.5 
(IQR 6.5 – 22.0).  Fifty-six percent of the PI-treated children received lopinavir/ritonavir and 70% of the 
NNRTI-treated children received efavirenz in their initial regimens.  There were no statistically significant 
differences in baseline demographic or clinical characteristics between treatment arms. 
 
Growth, immunology and clinical parameters:  
Table 2 shows baseline and 4 year values for all parameters and changes from baseline to 4 years for the 
entire group. The 95% confidence intervals for these changes exclude zero for everything except CD8% 
and CD4/CD8 ratio. Table 3 compares changes over four years between study arms. Overall at 4 years 
there was no evidence of significant liver, kidney or hematologic dysfunction in either treated group. 
Growth, liver, kidney and hematologic parameters either did not show significant changes or improved 
between baseline and year 4.  Median alanine amino-transferase (ALT) and aspartate transferase (AST) 
levels and the AST platelet ratio index (APRI) were lower at year 4, with no difference between the PI vs 
NNRTI-treated children.  Hematologic parameters were stable with no evidence for significant 
neutropenia at year 4.  Hemoglobin levels rose slightly over the 4 years with a slightly greater increase 
noted in the NNRTI-treated group.  Cholesterol levels were higher at year 4 in the PI-treated group than 
in the NNRTI-treated group but the difference was not significant.  Triglyceride levels decreased in both 
groups over the 4 years, but as not all the samples were drawn in a fasted state, triglyceride levels were 
not included in the analysis. CD4 percent  increased from a median 16% (IQR 7,22) to 33% (IQR 25,39)at 
4 years, with an improvement in CD4/CD8 ratio and no difference by treatment group.   Height and 
weight z-scores improved in both groups with no difference between treatment arms. 
 
Inflammatory markers: All inflammatory markers showed decreases over the 4 years; the 95% 
confidence intervals for the decreases in IL-6 and D-Dimer did not include 0.  Both IL-6 and hsCRP 
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showed greater decreases after 4 years in the NNRTI-based ART group; these differences were 
statistically significant. The median change in IL-6 was -0.35 pg/ml in the PI group vs -1.01 pg/ml in the 
NNRTI group (p=0.05) and the median change in hsCRP was 0.25 µg/ml PI vs -0.95 µg/ml NNRTI (p=0.005).  
(Table 3).   
Sensitivity analysis: As nelfinavir is no longer a preferred PI, a sensitivity analysis was conducted 
excluding the 21 participants initially taking nelfinavir (supplemental table). The results were similar and 
all differences were in the same direction.  
 
Discussion 
Our data support the long-term safety of ART in children.  Although the importance of early ART for 
infants and symptomatic children is unquestioned13, the data for the benefit of starting ART for older 
asymptomatic children are less robust14.  All current international15,16 and most national guidelines17 
recommend starting all children with HIV on ART regardless of their age or CD4 cell count, however, 
there remain concerns for potential long-term toxicity of ART in children who may be stable 
immunologically for years before therapy is initiated18,19. Our data suggest children who are suppressed 
on therapy show little evidence of long-term renal, hepatic, or hematologic toxicity. Conversely, apart 
from total cholesterol, all parameters studied improved or were stable over 4 years.   
 
The toxicities of individual ARVs are well characterized171717. Most of these adverse effects improve with 
time on ART and the rate of ART discontinuation or switch is generally low20-22.  In addition, many of the 
newer ARVs are better tolerated and provide additional options for treatment should modifying ART due 
to intolerance become necessary.  Most studies of ART-associated toxicity in children report on only 
grade 3 or higher adverse events or are limited to short-term follow-up22-24 and include children on ART 
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but with elevated HIV RNA levels.  It can be difficult to sort the medication effects from the effects of 
active viral replication which itself can lead to elevations in liver enzymes25, neutropenia, 
thrombocytopenia and anemia26,27.  By selecting the subpopulation of PENPACT-1 participants who 
remained virologically suppressed throughout the study, the effect of HIV replication on the laboratory 
parameters studied was minimized.  
 
In the primary analysis of PENPACT-1, no differences in virologic outcome or serious adverse events 
were seen between the children randomized to PI vs NNRTI-based treatment10.  Similarly, in the subset 
of participants with suppressed viral replication represented in this analysis, there were no significant 
differences in markers of hepatic, renal or hematologic function over the 4 years in the groups treated 
with PI vs NNRTI-based ART. The only measured difference over the 4 years between the two groups 
was seen in the markers of inflammation, with a greater decrease in median hs-CRP and IL-6 levels in the 
children on suppressive NNRTI-based treatment.  The clinical significance of 
this finding is unclear. Our selected PENPACT-1 data provide valuable evidence in this regard for 
clinicians wishing to evaluate abnormal laboratory results in children on treatment. 
 
HIV infection has been associated with an increase in risk factors associated with development of 
cardiovascular disease in adults and children6,7,28-30.   The relative contributions of traditional 
cardiovascular disease risk factors, uncontrolled viral replication, immune activation, and antiretroviral 
medications continue to be investigated31,32. There was higher mortality in the HIV-infected adults 
treated episodically with ARVs compared to those who received continuous ARVs in the Strategies for 
Management of Anti-Retroviral Therapy Study33, with the majority of deaths due to non-HIV related 
causes. Further investigation in the SMART trial revealed mortality34,35 and risk of development of 
cardiovascular disease36 to be associated with plasma levels of Il-6, D-dimer, hs-CRP and sCD14 levels, 
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however only D-dimer was found to decrease significantly after 6 months of continuous ART in a 
subgroup of the SMART participants37.  While many studies have confirmed higher levels of 
inflammatory markers in HIV-infected adults38,39 and children40, treatment with ARVs has not 
consistently been shown to decrease inflammation.  D-dimer and/or IL-6 levels have been found to 
decrease after starting ARVs in some studies but not others 37,41-43 . However, ARV treatment has not 
resulted in decreased hs-CRP or sCD14 in most studies37,43-46.  [MA1]The[GTW2] populations in most of these 
studies included individuals with detectable HIV RNA, which could make interpretation difficult as 
elevated viral load has been shown to be associated with higher D-dimer and hs-CRP levels, although 
inconsistently40,42,44,47-49.  In our population of children with suppressed viral replication for 4 years, D-
dimer, IL-6, hs-CRP and sCD14 were stable or decreased on therapy with the greatest decrease seen in 
levels of IL-6 and D-dimer.  Our results are consistent with a recent report investigating inflammatory 
markers in HIV-infected adolescents with prolonged virologic control. In this cross-sectional study, 
sdCD14 levels were higher than uninfected controls after a median of 4-11 years of viral suppression, 
while IL-6 levels were similar to the uninfected controls, suggesting an effect of suppressive ART on IL-6 
but not sdCD14 levels 46.  
 
In our cohort, there was a greater decrease in the levels of IL-6 and hs-CRP in the NNRTI-treated 
children. Several studies have investigated the effects of PIs vs NNRTIs on inflammatory markers with 
conflicting results. IL-6 levels were lower in adults treated with nevirapine and efavirenz compared to PI-
50, but no effect of PI vs NNRTI treatment was found on IL-6 levels in adolescents changing therapy41.  
However, both of these studies were observational and the participants were not randomized to their 
ART regimens.   In a substudy of A520232 which randomized ART-naïve HIV-infected adults to 
tenofovir/emtricitabine or abacavir/lamivudine and to efavirenz or atazanavir/ritonavir, there was no 
difference in the decline of IL-6 levels after 96 weeks in participants randomized to efavirenz vs 
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atazanavir/rit and hs-CRP levels were unchanged from baseline in both groups. Our cohort is the only 
study investigating inflammatory markers in children randomized to initial ART. 
 
It is a strength of this analysis that all the participants were suppressed throughout follow-up; this 
makes it more likely that the results are related to the ARTs rather than effects of HIV viral replication. 
However, our study has several limitations, including a relatively small sample size.  The analysis was 
based on single measurements at two time-points and there was no requirement that children be free 
of minor illnesses at the time of study visits which may have impacted CRP and IL-6 in particular. The 
study is primarily exploratory, with some variables not available for all individuals, and analyses were 
not adjusted for multiple comparisons. The children were on various different regimens which did not 
allow a determination of the influence of specific NRTIs, NNRTIs or PIs.  In addition, there was no control 
group.  Because of this we do not know if similar changes would have been seen in healthy children or 
HIV-infected children who were on neither PI- or NNRTI-based ART regimens. 
Conclusion 
In this cohort of HIV-infected children with prolonged viral suppression after randomization to either a 
PI or an NNRTI-based ART regimen, we found that there were no significant differences in routine 
laboratory measures between the two randomized groups.  All parameters were stable or improved 
over the 4 years of treatment with the exception of total cholesterol which was higher at 4 years in both 
treatment groups.  There was however, indication of a greater decrease in biomarkers of inflammation 
in the NNRTI-treated group.  This may have implications for the choice of ART for long-term health of 
ART treated children. 
These results support the safety of prolonged ART use in HIV-infected children and suggest that 
suppressive NNRTI-based regimens may have some advantage in terms of decreased levels of systemic 
inflammation.   
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